FDA Recommends Removal of Voluntary Hold for Elevidys for Ambulatory Patients

For Immediate Release: July 28, 2025 The U.S. Food and Drug Administration is recommending the removal of the voluntary hold for ambulatory patients who may now receive Elevidys, a Sarepta Therapeutics gene therapy for Duchenne Muscular Dystrophy (DM... [806 chars]